Related Experiment Video

Updated: Jun 26, 2026

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
09:37

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging

Published on: July 14, 2016

Complement factor H (Y402H) polymorphism and risk of coronary heart disease in US men and women

Jennifer K Pai1, JoAnn E Manson, Kathryn M Rexrode

  • 1Department of Epidemiology, Harvard School of Public Health, 677 Huntington Avenue, Kresge 9th Floor, Boston, MA 02115, USA. jpai@hsph.harvard.edu

European Heart Journal
|May 8, 2007
PubMed

Insights

The Complement Factor H (CFH) Y402H variant showed an inverse association with coronary heart disease (CHD) risk in women, particularly those under 65. This genetic link suggests a protective effect in younger individuals.

Area of Science:

  • Genetics and Cardiovascular Disease
  • Molecular Epidemiology
  • Inflammation and Immunology

Background:

  • The Complement Factor H (CFH) Y402H polymorphism is located in a critical protein-binding region, potentially influencing inflammatory responses and coronary heart disease (CHD) risk.
  • Understanding genetic predispositions to CHD is crucial for targeted prevention strategies.

Purpose of the Study:

  • To investigate the association between the CFH Y402H polymorphism and the risk of developing coronary heart disease (CHD).
  • To examine potential sex-specific differences and age-related effects in this association.

Main Methods:

  • Nested case-control studies were conducted within two large prospective cohorts: US male health professionals and female nurses.
  • Participants were followed for incident CHD deaths and non-fatal myocardial infarctions (MIs).
  • Risk-set sampling was used for control selection, matched on age, smoking status, and blood draw date.

Main Results:

  • A significant inverse association was observed between the CFH Y402H homozygous HH genotype and CHD risk in women (RR 0.51).
  • This inverse association was more pronounced in individuals younger than 65 years at the time of CHD onset (pooled RR 0.30).
  • No significant association was found in men or in individuals aged 65 years or older.

Conclusions:

  • The CFH Y402H polymorphism is inversely associated with CHD risk, particularly in women and younger individuals.
  • These findings highlight the role of complement factor H genetics in cardiovascular health and suggest potential age- and sex-specific effects.
Abstract

More Related Videos

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

Related Concept Videos

Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...